High doses of TRAM-34 administered to rodents over many weeks are well tolerated [13] and the orally available KCa3.1 blocker, ICA-17043, has been administered to humans in phase 2 and 3 trials of sickle cell disease with minor side effects [40]. This evidence concerns the gene KCNN4 and sickle cell disease.